|
 |
FerrlecitThis page contains recent news articles, when available, and an overview of Ferrlecit but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.1 the company will also exclusively sell the injectable iron product Ferrlecit, used to treat iron-deficiency anemia in end-stage renal disease patients on ... NephrOnline Skinvisible Inks Canadian Agreement For DermSafe - Dec 11, 2009 Inc. (NYSE: WPI) said it has inked a license agreement with GeneraMedix, Inc., for the exclusive US marketing rights to a generic version of Ferrlecit,. ... India Business Blog (blog) Generex Inks Deal With Sanofi-Aventis For Insulin Supply - Dec 11, 2009 Inc. (NYSE: WPI) said it has inked a license agreement with GeneraMedix, Inc., for the exclusive US marketing rights to a generic version of Ferrlecit,. ... India Business Blog (blog) Watson Announces New Program to Help Promote Good Bone Health in Advanced ... - Dec 14, 2009 In the US, the Watson portfolio includes RAPAFLO, GELNIQUE, Oxytrol®, TRELSTAR® LA and TRELSTAR® Depot, Ferrlecit®, and INFeD®. In addition, Watson markets ... CNNMoney.com (press release) Watson Pharmaceuticals Q3 2009 Earnings Call Transcript - Nov 4, 2009 As expected, we continue to see declines in the sales of Ferrlecit due to customers switching to a competitor's product. As we announced last quarter, ... Seeking Alpha (blog) BioTrends Releases Three Publications - TreatmentTrends(R): US Nephrology ... - Nov 5, 2009 ...remains -- will practitioners switch from established IV iron brands (such as Venofer and Ferrlecit) for an agent that is simply more convenient? ... Reuters Watson Pharma Beats by a Penny - Nov 4, 2009 Contributions from new products, Rapaflo and Gelnique, and increased sales of Androderm were partially offset by lower sales of Ferrlecit. ... Zacks.com Ein unbequemer Häftling - Nov 9, 2009 Nur sei die Kobalt-Ferrlecit-Injektion bei Kalinka "auf einen unglücklichem Umstand" getroffen, der ihren Tod zur Folge gehabt habe. ... WELT ONLINE "Er wird wie ein Volksheld gefeiert" - Oct 22, 2009 Später soll K. Akten zufolge behauptet haben, er habe die Kobalt-Ferrlecit-Injektion nicht vor, sondern nach dem Abendessen gegen 20.30 Uhr verabreicht. ... Spiegel Online Profit pinch at Corona, Calif., drug maker. - Feb 11, 2005 Ferrlecit, a drug for treating anemia, is Watson's leading product and accounts for about 10 percent of the company's total sales, said Watson spokesman ... Free with registration - Press-Enterprise - AccessMyLibrary.com AMAG Pharmaceuticals Ferumoxytol Not likely to Capture Market share - Jan 28, 2008 This new iron preparation offers no benefit over Ferrlecit and Venofer. ... 8 30 minute infusions of Ferrlecit is extremely effective and safe. ... Gerson Lehrman Group Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2004 … - Feb 10, 2005 Accordingly, amortization expense on FERRLECIT(R) product rights and related intangibles ... Regulatory exclusivity on FERRLECIT(R) expired in August, 2004, ... $4.95 - PR Newswire - ECNext Profit pinch at Corona, Calif., drug maker. | Article from Press... - Feb 11, 2005 Ferrlecit, a drug for treating anemia, is Watson's leading product and accounts for about 10 percent of the company's total sales, said Watson spokesman ... Pay-Per-View - Press-Enterprise - HighBeam Research Goldman downgrades Watson to sell; urges short sale - Sep 16, 2008 Analyst Randall Stanicky said he sees clear earnings risk for Watson from its iron deficiency treatment, Ferrlecit. He expects declining revenue in 2009 ... Reuters Drug maker hedges against rivals. - May 16, 2005 The company received the rights to Ferrlecit in May 2000 after acquiring the original manufacturer, Schein Pharmaceutical Inc. in New Jersey, ... Free with registration - Business Press - AccessMyLibrary.com Federal Register 2005 - 70 FR 15636 Summaries of Medical and Clinical - Mar 28, 2005 TAMIFLU (oseltamivir), VIOXX (rofecoxib), FERRLECIT (sodium ferric gluconate), IMITREX (sumatriptan), DETROL and DETROL LA (tolterodine). ... Pay-Per-View - Federal Register 2005 - Loislaw Watson Pharmaceuticals, Morristown, NJ, May 2 (DDMAC).(CFSAN and … - Jun 1, 2005 According to the FDA-approved labeling, Ferrlecit is a hematinic agent ... DDMAC also took issue because the ad for Ferrlecit failed to disclose any risk ... $4.95 - Warning Letter Bulletin - ECNext Watson Pharmaceuticals, Inc. at CIBC World Markets Annual … - Apr 4, 2006 Nephrology obviously has two major products, FERRLECIT and (indiscernible) two major ... And Nephrology continues support by FERRLECIT (indiscernible). ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Intravenous Iron in the Management of Chemotherapy-Induced Anemia: … - Jun 1, 2007 The intravenous iron preparation used was either ferric gluconate (Ferrlecit) or iron saccharate (Venofer). The two groups were similar in age and ... Cancer Consultants BioTrends Releases Two Publications - TreatmentTrends(TM): … - May 6, 2008 The majority of Nephrologists continue to view American Regent's Venofer and Watson's Ferrlecit as interchangeable. Venofer and Ferrlecit are perceived to ... RedOrbit Watson Pharmaceuticals Inc. - Jun 19, 2006 ...uct is Ferrlecit, which is indicated for patients undergoing hemodialysis in conjunction with ... Ferrlecit accounted for about 9% of revenues in 2005. ... $35.00 - Stock Reports - Standard & Poor's Press Release: BioTrends Releases Two Publications - TreatmentTrends(... - May 6, 2008 The majority of Nephrologists continue to view American Regent's Venofer and Watson's Ferrlecit as interchangeable. Venofer and Ferrlecit are perceived to ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Hagens Berman: Eleven Defendants Settle in Average … - Mar 7, 2008 Steve Berman, Hagens Berman managing partner ... Ferrlecit and Infed. Medicare Part B recipients eligible ... settlement to Medicare Part B Zoladex ... ... Pay-Per-View - PR Newswire - HighBeam Research Event Brief of Q4 2004 Watson Pharmaceuticals, Inc. Earnings … - Feb 10, 2005 On FERRLECIT and the acceleration of the amortization schedule, I would assume that ... On FERRLECIT, does your amortization of the asset value through Dec. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Thema: Herzstolpern und Ferritin - Apr 20, 2007 Ich bekam daraufhin 1 x wöchentlich Eiseninfusion mit Ferrlecit. ... Seit Montag nun Präparatwechsel von Ferrlecit auf Venofer (dreiwertiges Eisen), ... Vitanet GmbH Watson 1st-quarter profit rises 60 percent - May 1, 2008 Sales from the company's higher-margin brand-name drug segment increased nearly 14 percent to $115 million, helped by demand for its Ferrlecit ... Reuters Drug maker hedges against rivals. | Article from Business Press (San ... - May 16, 2005 The company received the rights to Ferrlecit in May 2000 after acquiring the original manufacturer, Schein Pharmaceutical Inc. in New Jersey, ... Pay-Per-View - Business Press - HighBeam Research EDITED BRIEF - May 1, 2008 Significant decline in amortization related to Ferrlecit product rights. 3. Continued to view 2008 as a transitional year. ... $54.00 - Thomson StreetEvents - Alacra Store le Parisien - Archives Actualité - Archives - 01/01/1970 - Jul 5, 2007 ...plusieurs boîtes de ferrlecit » (du fer sous forme injectable), ainsi que de « vitamine B12 et d'acide folique ». « Ce fer injectable est troublant. ... Le Parisien Deutsche Morbus Crohn / Colitis ulcerosa Vereinigung eV: DCCV-Forum - Mar 21, 2008 ...weil ich Ferrlecit (62,5 mg iv, als Kurzinfusion in NaCl) oft schlecht vertrage, bestellte mein Arzt ein neues Eisenpräparat. ... DCCV Fourth Quarter 2005 Results - Feb 16, 2006 ...$22.8 million to $41.1 million in the fourth quarter 2005, representing an increase in amortization of the Company's Ferrlecit(R) intangible asset. ... Free with registration - PR Newswire - AccessMyLibrary.com Watson Pharma swings to profit - Feb 20, 2008 Brand product sales decreased 3 percent to $94.1 million, mainly on lower sales of iron deficiency anemia treatments INFeD and Ferrlecit. ... Forbes Analysts' Upgrades, Downgrades: AIG - Sep 16, 2008 Watson Pharmaceutical (WPI Quote) was downgraded at Goldman to Sell from Neutral based on earnings risk from Ferrlecit and potentially costly expansion ... TheStreet.com - TheStreet.com (subscription) Watson Pharmaceuticals, Inc. at CIBC World Markets 17th Annual … - Nov 8, 2006 Two major products, Ferrlecit and INFeD. And in the urology field, we have Trelstar, Oxytrol. We obviously have some pipelines. In addition to that we have ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Efficacy and Tolerability of Intravenous Ferric Gluconate in the... - Jun 25, 2007 1 Intravenous (IV) ferric sodium gluconate (Ferrlecit; Sanofi-Aventis, Dagenham, England) is FDA approved for the treatment of iron deficiency anemia ... Archives of Internal Medicine BUSINESS BRIEFING / PHARMACEUTICALS; DaVita receives US … - Dec 16, 2008 ...s Venofer, Genzyme Inc.'s Hectorol and Watson Pharmaceuticals Inc.'s Ferrlecit, according to a statement. DaVita said it was working with officials from the ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Onmark Signs Contracts with Two Additional Pharmaceutical … - Jun 1, 2006 Onmark recently signed new contracts with Watson Pharmaceuticals for Ferrlecit(R) (sodium ferric gluconate complex in sucrose injection) and INFeD(R) (iron ... Free with registration - PR Newswire - AccessMyLibrary.com Event Brief of Q4 2005 Watson Pharmaceuticals, Inc. Earnings … - Feb 16, 2006 In nephrology, the Co. sees steady growth of Ferrlecit unit. sales. 6. Successes: 1. Last year, Trelstar exceeded original forecast by many million dollars. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Daiichi Drug Backed With Restrictions by US Panel - Feb 1, 2008 On occasion, doctors may use the intravenous drugs Venofer, sold by Daiichi, and Ferrlecit, sold by Watson Pharmaceuticals Inc., which are approved for ... Bloomberg Watson Pharmaceuticals, Inc. - Sep 17, 2007 Key products include Ferrlecit, an intravenous iron for use in the dialysis setting; Trelstar, an LHRH agonist for treating advanced prostate cancer; ... $9.94 - Chain Drug Review - Alacra Store Refractory anemia in a patient with allergy to intravenous iron drugs - Apr 19, 2006 Michael B, Coyne DW, Fishbane S, et al., Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions ... Nature.com Press Release: New Hope for Pets with Chronic Kidney Disease. - PR … - Apr 4, 2007 2008 ; 700+ words ... ... with later stage Chronic Kidney Disease (CKD) patients, and qualitative interviews ... market over Watson's Ferrlecit. ... Pay-Per-View - PR Newswire - HighBeam Research Daiichi Sankyo Drug Poses Risks, US FDA Staff Says - Jan 30, 2008 Injectafer would compete with the drug Venofer, already sold by a US unit of Daiichi, and Ferrlecit, sold by Watson Pharmaceuticals Inc., said Carol Werther ... Bloomberg Abstract and Introduction - May 5, 2006 A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients ... Medscape Press Release: Cytochroma initiates Phase I/II clinical trial of... - Nov 20, 2007 2008 ; 700+ words ... ... working with later stage Chronic Kidney Disease (CKD) patients, and qualitative interviews ... over Watson's Ferrlecit. ... Pay-Per-View - PR Newswire - HighBeam Research Fitch Downgrades Watson's Ratings to 'BBB-'. - Nov 6, 2006 Ltd.), the next generation of Oxytrol, a new indication for Ferrlecit, and a fixed dose combination of Actos and extended-release metformin. ... Free with registration - Business Wire - AccessMyLibrary.com Event Brief of Q3 2005 Watson Pharmaceuticals, Inc. Earnings … - Nov 2, 2005 The Ferrlecit/INFeD mix remains in line with the Co.'s expectations and was approx. 83% to 17% for 3Q05. 6. Outlook: 1. For 2005, brand division revenues ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Top 200 drugs used in hospitals in 2006.(Table) - Apr 16, 2007 64730815.04 3.63 132 Ampicillin Sodium 64485701.12 49.22 133 Potassium Chloride 64371359.23 10.30 134 Ferrlecit 64096716.00 5.72 135 Lexapro 63726957.39 ... $4.95 - Drug Topics - ECNext Pumping iron: new drugs and revamped guidelines are expected to usher... - Jan 23, 2006 American Regent), after which iron can be reliably determined 48 hours after the last dose, and iron gluconate (Ferrlecit, Watson Pharmaceuticals), ... Free with registration - Drug Topics - AccessMyLibrary.com Watson Pharmaceuticals Reports Third Quarter 2005 Results - Sep 30, 2005 ...product rights increased $23.1 million to $41.1 million, representing an increase in amortization of the Company's Ferrlecit(R) intangible asset. ... Euro am Sonntag Anemia: focus on common types and treatment.(CONTINUING … - Jul 23, 2007 Three commercial products are available in this formulation: iron dextran (InFeD and Dexferrum), sodium ferric gluconate (Ferrlecit), and iron sucrose ... $4.95 - Drug Topics - ECNext Watson Pharmaceuticals Reports Second Quarter 2005 Results. - Jul 27, 2005 ...product rights increased $23 million to $41.1 million, representing an increase in amortization of the Company's Ferrlecit(R) intangible asset. ... $4.95 - PR Newswire - ECNext United States top 200 brand and generic drugs used in hospitals in … - Jun 19, 2006 164344840.22 15.39 129 Isovue-300 164190574.00 -0.28 130 Altace 163938877.26 11.81 131 OxyContin 162855456.13 -22.22 132 Ferrlecit 161593131.00 0.60 133 ... $20.00 - Drug Topics - Alacra Store Watson Pharmaceuticals Reports Second Quarter 2008 Results - Aug 6, 2008 Amortization expense for the second quarter 2008 declined $24.0 million to $20.2 million , reflecting the full amortization of Ferrlecit(R) product rights ... Genetic Engineering News - Genetic Engineering News (press release) Watson Pharmaceuticals Reports Third Quarter 2005 Results. - Nov 2, 2005 ...product rights increased $23.1 million to $41.1 million, representing an increase in amortization of the Company's Ferrlecit(R) intangible asset. ... $4.95 - PR Newswire - ECNext Loislaw Federal District Court Opinions - BIO-MEDICAL APPLICATIONS … - Jan 25, 2006 ...or EPO, a hormone which regulates red blood cell production, and Ferrlecit, an iron supplement used to treat iron depletion caused by EPO. ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Sumatriptan, fluconazole called safe too.(News) - Dec 15, 2005 ...agent Paraplatin (carboplatin), platelet-reducing agent Agrylin (anagrelide), and hematinic agent Ferrlecit (sodium ferric gluconate complex). Pay-Per-View - Family Practice News - Factiva, from Dow Jones Pure Nickel Inc acquires Red Dragon-Axis Lake Nickel from Red Dragon ... - May 25, 2006 Ferrlecit (Sodium Ferric Gluconate Complex) Red Blood Cell (RBC) Disorders Anemia…Products: Hepatitis C Therapeutic ProVax PURE Bioscience ( PURE ... Pay-Per-View - deals - Alacra Store BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report … - Jul 25, 2008 ...position as market leader in both dialysis and CKD, the majority of Nephrologists continue to view Venofer and Watson's Ferrlecit as interchangeable. ... Genetic Engineering News - Genetic Engineering News (press release) ESAs and IV iron: a perfect match? - Aug 10, 2008 In addition to low-molecular weight iron dextran, two other iron preparations, iron sucrose (Venofer, American Regent) and ferric gluconate (Ferrlecit, ... HemOncToday ESA use in CKD patients decreases due to managed care policies, … - Jul 28, 2008 ...position as market leader in both dialysis and CKD, but the majority of surveyed nephrologists view Venofer and Watson's Ferrlecit as interchangeable. ... Renal Business Today Watson's OAI lifted and Goa manufacturing transfer on track - May 5, 2008 Product sales increased 9 per cent due to an improved contribution from Ferrlecit (sodium ferric gluconate) and Trelstar (triptorelin palmoate). ... In-PharmaTechnologist.com Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2005 … - Sep 10, 2008 ...$22.8 million to $41.1 million in the fourth quarter 2005, representing an increase in amortization of the Company's Ferrlecit(R) intangible asset. ... Euro am Sonntag New Study by BioTrends Highlights Practice Management Shifts Among … - Nov 19, 2008 American Regent's Venofer is the market share leader in both dialysis and CKD, but their margin over Watson's Ferrlecit is greater in CKD. ... International Business Times Press Release: Most Americans Unfamiliar With Risks From Chronic … - Nov 10, 2006 2008 ; 700+ words ... ... with later stage Chronic Kidney Disease (CKD) patients, and qualitative interviews ... market over Watson's Ferrlecit. ... Pay-Per-View - PR Newswire - HighBeam Research Federal Register 2005 - 70 FR 67179 Pediatric Advisory Committee; … - Nov 4, 2005 CAMPTOSAR (irinotecan), TAMIFLU (oseltamivir), VIOXX (rofecoxib), FERRLECIT (sodium ferric gluconate complex), and IMITREX (sumatriptan). ... Pay-Per-View - Federal Register 2005 - Loislaw Loislaw Federal District Court Opinions - BIO-MEDICAL APPLICATIONS … - Jan 20, 2006 ...or EPO, a hormone which regulates red blood cell production, and Ferrlecit, an iron supplement used to treat iron depletion caused by EPO. ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw USA biotech: AMAG shares double on news of quicker FDA review - Nov 17, 2008 There are two "well entrenched" existing formulations -- Venofer and Ferrlecit, according to Sanchez's research. More than 80 percent of IV iron use occurs ... $34.00 - EIU Country Analysis - Alacra Store Drug-makers agree to $125M settlement in US District Court in Boston... - Mar 12, 2008 Drugs covered in this settlement include: Aranesp, Epogen, Neupogen, Neulasta, Anzemet, Ferrlecit and Infed. Under the terms of the settlement, 82.5 percent ... Pay-Per-View - Lawyers USA - HighBeam Research Press Release: European Nephrologists Share Insights on the … - Dec 2, 2008 Venofer and Ferrlecit are the most familiar brands to Nephrologists with market share varying by country. Newcomer Ferinject (ferric carboxymaltose) has yet ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: New Study by BioTrends Highlights Practice Management … - Nov 19, 2008 American Regent's Venofer is the market share leader in both dialysis and CKD, but their margin over Watson's Ferrlecit is greater in CKD. ... Pay-Per-View - PR Newswire - HighBeam Research Competitors by Product Report - Nov 8, 2008 Watson Pharmaceuticals, Inc. (WPI) Products:. Ferrlecit (Sodium Ferric Gluconate Complex). Research/Preclinical Stage Products ... $75.00 - Revere - Alacra Store Watson swings to profit of $38.4M in 4th qtr. - Mar 3, 2008 ...where sales fell 3% to $94.1 million, primarily due to lower sales of iron replacement product INFeD and Ferrlecit (sodium gluconate) for the treatment ... $9.94 - Pharma Marketletter - Alacra Store Gout in dialysis patients tied to higher mortality risks.(Clinical... - Mar 15, 2008 Ferrlecit, a nondextran injectable iron supplement, has been granted Food and Drug Administration approval for treatment of iron deficiency anemia in ... Pay-Per-View - Family Practice News - HighBeam Research Press Release: BioTrends Releases Quarterly TreatmentTrends(TM): … - Jul 25, 2008 ...position as market leader in both dialysis and CKD, the majority of Nephrologists continue to view Venofer and Watson's Ferrlecit as interchangeable. ... Pay-Per-View - PR Newswire - HighBeam Research Watson's 1st-qtr 2008 net income jumps 60%. - May 12, 2008 Brand product turnover increased 9% to $99.0 million, thanks to higher sales of Ferrlecit (sodium gluconate) for the treatment of iron deficiency anemia and ... $9.94 - Pharma Marketletter - Alacra Store Competitors by Product Report - Nov 8, 2008 Watson Pharmaceuticals, Inc. (WPI) Products:. Ferrlecit (Sodium Ferric Gluconate Complex). Research/Preclinical Stage Products ... $75.00 - Revere Reports - Revere Competitors by Product Report - Mar 8, 2008 Ferrlecit (Sodium Ferric Gluconate Complex). White Blood Cell (WBC) Disorders. Myelodysplastic Syndromes (MDS). Antimetabolite Agents. Pyrimidine Analogs ... $75.00 - Revere Reports - Revere Press Release: Hagens Berman: Eleven Defendants Settle in Average … - Mar 8, 2008 Drugs covered in this settlement include Aranesp, Epogen, Neupogen, Neulasta, Anzemet, Ferrlecit and Infed. Read all of this article with a FREE trial ... Pay-Per-View - PR Newswire - HighBeam Research Die Packungen von sanofi–aventis in neuem Design - Apr 19, 2006 L-Polamidon®, Cordarex®, Amiodarex®, Ferrlecit® sowie Arava® werden ab April, Lasix® und Profact® im September folgen. Insgesamt werden über einen Zeitraum ... journalmed.de Article: Using CQ1 strategies to improve and simplify IV iron and... - Sep 1, 2005 Article: Schein Pharmaceutical is Now Shipping Ferrlecit(R) - New ... PR Newswire; June 17, 1999 ; 700+ words ... ... iron deficient anemic chronic ... Pay-Per-View - Nephrology Nursing Journal - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |